Cannabis-Induced Acute Pancreatitis; Bleomycin-Induced Flagellate Hyperpigmentation; Risperidone-Associated Hypocalcemia; Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) Syndrome Associated with Clindamycin; New-Onset Psychosis in Depressed Patient Treated with Aripiprazole; Emergency Re-admissions to Hospital Due to Adverse Drug Reactions within 1 Year of Index Admission; Inhaled Corticosteroids and the Risks of Diabetes Onset and Progression; Angiotensin-Converting Enzyme Inhibitors and Associated Cough

2011 ◽  
Vol 46 (2) ◽  
pp. 87-90 ◽  
Author(s):  
Joel Shuster
Keyword(s):  
Enzyme Inhibitors ◽  
Inhaled Corticosteroids ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Drug Reactions ◽  
Dress Syndrome ◽  
Converting Enzyme Inhibitors ◽  
Diabetes Onset ◽  
Drug Rash ◽  
Systemic Symptoms ◽  
New Onset

scholarly journals Therapeutic Trial of Rifabutin After Rifampicin-Associated DRESS Syndrome in Tuberculosis-Human Immunodeficiency Virus Coinfected Patients

2016 ◽  
Vol 3 (3) ◽  
Author(s):  
Rannakoe J. Lehloenya ◽  
Sipho Dlamini ◽  
Rudzani Muloiwa ◽  
Betty Kakande ◽  
Mzudumile R. Ngwanya ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Clinical Management ◽  
Cross Reactivity ◽  
Therapeutic Trial ◽  
Drug Reactions ◽  
Dress Syndrome ◽  
Drug Eruptions ◽  
Immunodeficiency Virus ◽  
Drug Rash ◽  
Systemic Symptoms

Abstract Elimination of a rifamycin from the treatment regimen for tuberculosis negatively impacts outcomes. Cross-reactivity between the rifamycins after drug eruptions is unclear. We report 6 consecutive human immunodeficiency virus-infected patients with rifampicin-associated drug rash with eosinophilia and systemic symptoms (DRESS) syndrome confirmed on diagnostic rechallenge. The patients subsequently tolerated rifabutin. These data inform clinical management of tuberculosis-associated drug reactions.

Abstract 11815: Effects of Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers and Beta-Blockers on the Prevention of Atrial Fibrillation in Patients With Heart Failure With Preserved Ejection Fraction: A Prospective Study of Four-Years Follow-Up

Circulation ◽  
2014 ◽  
Vol 130 (suppl_2) ◽  
Author(s):  
Masanori Kawasaki ◽  
Ryuhei Tanaka ◽  
Shingo Minatoguchi ◽  
Takatomo Watanabe ◽  
Maki Saeki ◽  
...  
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Diastolic Dysfunction ◽  
Enzyme Inhibitors ◽  
Beta Blockers ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Angiotensin Ii Receptor ◽  
Converting Enzyme Inhibitors ◽  
Significant Difference ◽  
New Onset

Background: The incidence of new-onset atrial fibrillation (AF) is increasing with the prevalence of diastolic dysfunction. Diastolic dysfunction is thought to be responsible for heart failure with preserved ejection fraction (HFPEF). Effective medication for the treatment of HFPEF has been controversial, although angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs) and beta-blockers (BBs) have been proven to be effective in heart failure with reduced EF. We recently reported that pulmonary capillary wedge pressure (ePCWP) estimated by the combination of left atrial (LA) volume (V) and emptying function (EF) evaluated by speckle tracking echocardiography (STE) had a strong correlation with PCWP measured by cardiac catheterization (r=0.86-0.92). Methods: We screened 663 elderly (>65 years old) patients and identified 228 who had no AF history and met the criteria for diastolic dysfunction according to the Echocardiography Association of the European Society of Cardiology. These patients were prospectively followed for 4 years to identify new-onset AF. We measured echocardiographic parameters such as left ventricular (LV) mass index, LV ejection fraction, E/A, E/e’ and ePCWP at baseline. Concomitant medication was left to the discretion of the physicians in charge. Results: During a mean follow-up of 43 months, 63 elderly patients (age 73±6, 39 men) developed electrocardiographically-confirmed AF. There was no significant difference in the development of new-onset AF between the groups treated with and without BBs (hazard ratio (HR): 0.615, p=0.15). There was also no significant difference in new-onset AF between the groups with and without ACEIs or ARBs (HR: 0.796, p=0.46). However, in multivariate analysis that included ePCWP, LVM index, E/e’ and E/A, ePCWP at baseline independently predicted the risk of new-onset AF (HR: 1.42, 95% confidence interval: 1.29-1.57, p<0.001). Conclusions: ACEIs, ARBs or BBs had no beneficial effects on the prevention of new-onset AF as a marker of diastolic dysfunction in the patients with HFPEF. Estimation of ePCWP by STE had incremental value for the risk stratification of new-onset AF.

Drug Rash With Eosinophilia and Systemic Symptoms (DRESS) Syndrome Probably Related to Cefpodoxime: A Case Report

2019 ◽  
pp. 089719001986609 ◽  
Author(s):  
Tirin Babu ◽  
George Mathew Panachiyil ◽  
Juny Sebastian ◽  
Veeranna Shastry
Keyword(s):  
Case Report ◽  
Signs And Symptoms ◽  
Side Effect Profile ◽  
Drug Reactions ◽  
Dress Syndrome ◽  
First Case ◽  
Drug History ◽  
Drug Rash ◽  
Systemic Symptoms ◽  
Favorable Side Effect Profile

Cefpodoxime is a common antibiotic with a favorable side effect profile. Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome has been described with several cephalosporins but not cefpodoxime. We report the probable first case of cefpodoxime-induced DRESS syndrome in a 52-year-old female patient. In our case, the patient presented with symptoms of DRESS syndrome 16 days after initiation of cefpodoxime. This case highlights the necessity of consideration of an iatrogenic reason for presenting signs and symptoms at all times. Reinforcing the importance of taking a thorough drug history and considering drug reactions even if onset of symptoms are delayed.

scholarly journals Prescribing pattern and adverse drug reactions of cardiovascular drugs in out-patient department of a tertiary care hospital

2019 ◽  
Vol 8 (4) ◽  
pp. 767
Author(s):  
Nalini R. ◽  
Mansoora Shahiba R. ◽  
Ezhil Ramya J. ◽  
Kannan S. M.
Keyword(s):  
Angiotensin Converting Enzyme ◽  
Adverse Drug Reactions ◽  
Enzyme Inhibitors ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Cardiovascular Drugs ◽  
Converting Enzyme ◽  
Drug Reactions ◽  
Prescribing Pattern ◽  
Converting Enzyme Inhibitors ◽  
The World

Background: The main objective of prescription pattern analysis is to assess the rationality of drug use. It has been found that cardiovascular disease is the most frequent cause of morbidity and mortality throughout the world. This study is to estimate the prescribing pattern and adverse drug reactions in patients with cardiovascular diseases.Methods: This prospective observational study was conducted for a period of 2 months in cardiology outpatient department.100 patients who fulfilled the study criteria were observed. The central drug standard control organisation (CDSCO) reporting forms were used for the collection of adverse drug reactions. Causality assessment was done by using the World Health Organization Collaborating Centre for International Drug Monitoring, the Uppsala Monitoring Centre (WHO-UMC) scoring system and severity assessment by modified Hartwig and Siegel scale.Results: The study group consists of 79% male and 21% females. Average number of drugs per prescription was 4.65. Most commonly prescribed drugs were antiplatelets (32%) followed by statins (18.27%) and the least common were calcium channel blockers (1.72%) and cardiac glycosides (0.86%). A total of 174 adverse drug reactions were reported out of which 24.7% were myalgia due to statins, 15.5% were cough due to angiotensin converting enzyme inhibitors and 14.3% were gastritis due to antiplatelets.Conclusions: Antiplatelets, statins and angiotensin converting enzyme inhibitors dominated the prescribing pattern. Myalgia, cough, gastritis, insomnia by atorvastatin, enalapril, aspirin, beta blockers respectively were found to be the most commonly reported ADRs among the cardiovascular drugs.

scholarly journals DEVELOPMENT AND VALIDATION OF A NOVEL METHOD FOR CAUSALITY ASSESSMENT USING SUSPECTED ADVERSE DRUG REACTIONS TO ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

2019 ◽  
pp. 359
Author(s):  
Rupinder Kaur Sodhi
Keyword(s):  
Phase I ◽  
Assessment Tool ◽  
Enzyme Inhibitors ◽  
Causality Assessment ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Test Reliability ◽  
Phase Iii ◽  
Drug Reactions ◽  
Converting Enzyme Inhibitors ◽  
Suspected Adverse Drug Reactions

Objectives: The study has been designed to develop, test reliability, and construct validity of a novel versatile causality assessment tool (VCAT) method. Methods: The study included 427 literature case reports of angiotensin-converting enzyme inhibitors with suspected adverse drug reactions from 1990 to February 25, 2016. The causality of these cases was assessed independently by 3 raters in 3 phases of the study. Kappa (k) and intra-class correlation Intraclass Correlation Coefficient (ICC) were used to test reliability and validity of the VCAT method. Results: Intra-rater reliability was high between Phase I and Phase III (k=0.84–0.93; % agreement: 92.3–96.3%). Inter-rater agreement was good in Phase I (k=0.87–0.89, % agreement: 93.7–94.1%, ICC: 0.975) and Phase III (k=0.85–0.89, % agreement: 93–94.4%, ICC: 0.973). Validity was proved by the high agreement observed between Phase I and Phase II (k=0.78–0.94; % agreement: 89.7–97.2%; p<0.001); and between Phase II and Phase III (k=0.8–0.9; % agreement: 90.2–94.8%; p<0.001). Conclusion: VCAT method is a standardized causal assessment tool that gives valid and reproducible results. It has shown good agreement with the expert judgment method. This method may overcome the limitations enthralled with existing methods of causality assessment.

Drugs

2018 ◽  
Author(s):  
Lesley K. Bowker ◽  
James D. Price ◽  
Ku Shah ◽  
Sarah C. Smith
Keyword(s):  
Older Patients ◽  
Drug Sensitivity ◽  
Enzyme Inhibitors ◽  
Oral Anticoagulants ◽  
Direct Oral Anticoagulants ◽  
Herbal Medicines ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Drug Reactions ◽  
Converting Enzyme Inhibitors ◽  
Drug History

This chapter provides information on pharmacology in older patients, prescribing ‘rules’, taking a drug history, drug sensitivity, adverse drug reactions, angiotensin-converting enzyme inhibitors, analgesia, steroids, warfarin, direct oral anticoagulants, proton pump inhibitors, herbal medicines, and breaking the rules.

Sign in / Sign up

Export Citation Format

Share Document